The treatment of leishmaniasis often requires a long course of intravenous pentavalent antimony drugs (e.g. Glucantime and Pentostam), aminosidine (paromomycin) or liposomal amphotericin B (Croft & Coombs, 2003; Center for Food Security and Public Health, 2004; WHO, 2004; Kedzierski et al. 2009). The most recent addition was the orally available miltefosine (Sunder et al. 2002; Verma & Dey, 2004), originally developed as anti-neoplastic agent. Despite its teratogenic effects (Sunder et al. 2002), due to the lack of other effective medications, it has been registered and is now used in India, Colombia, Guatemala and Germany (Soto & Berman, 2006). Other regimens of treatment include Pentamidine (Bray et al. 2003), allopurinol, dapsone, fluconazole, itraconazole and ketoconazole. However, to-date all available chemotherapeutic agents suffer from being toxic (Chappuis et al. 2007) or inaccessible, both geographically and financially, in endemic areas where public health is under-resourced, poor and underdeveloped. Additionally, the lack of effective vaccines (de Oliveira et al. 2009) and the alarming emergence of resistance to these drugs (Croft et al. 2006), combined with the short-lived prevention resulting from applying measures such as vector and reservoir host control (WHO, 2004; Figueiredo et al. 2012), demand an intensive search for alternative anti-leishmanials to enable effective treatment and control.